Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Concentrations of Remifentanil for Extubation (REMEX)

16 maart 2016 bijgewerkt door: LUIS ALBERTO TAFUR B, Seganest

Effect of Two Plasma Concentrations of Remifentanil Through Target Controlled Anesthesia on Frequency and Intensity of Coughing During Extubation: Randomized Controlled Clinical Trial

Condition of the State: (terminated, recruiting, etc.) Terminated

Study Design: Main Objective:

Compare the frequency and intensity of coughing at the time of extubation with two infusions of remifentanil that predict a plasma concentration (PC) of 3 - 4 and 2 - 3 ng/ml, through the technique of target controlled anesthesia

Studie Overzicht

Toestand

Voltooid

Conditie

Gedetailleerde beschrijving

Phase of the study:

Phase IV

Intervention:

Drug: U Extubation

Other Names:

Concentration 2 - 3 ng/ml Dose of remifentanil according to the randomization: Letter U between 2 - 3 ng/ml. The infusions that were used to reach the (PC) target were: Group U = 2 - 3 ng/ml. 20 years old - 6.0 mcg/Kg/h, 30 years old - 5.7 mcg/Kg/h, 40 years old - 5.3 mcg/kg/h, 50 years old - 5.0 mcg/kg/h, 60 years old - 4.6 mcg/kg/h, 70 years old - 4.3 mcg/kg/h, 80 years old - 4.0 mcg kg/h.

Drug: Extubation T

Other Names:

Concentration 3 - 4 ng/ml Dose of infusion of remifentanil to reach a (PC) 3 - 4 ng/ml, in the following manner: The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient. The remifentanil dose was adjusted according to the randomization: Group T = 3 - 4 ng/ml. 20 years old - 9.0 mcg/Kg/h, 30 years old - 8.5 mcg/Kg/h, 40 years old - 8.0 mcg/kg/h, 50 years old - 7.5 mcg/kg/h, 60 years old - 7.0 mcg/kg/h, 70 years old - 6.5 mcg/kg/h, 80 years old - 6.0 mcg kg/h.

Number of arms:

2

Masking:

The patient had masking with regards to the anesthetic procedure from the unfamiliarity per se of the same and by agents used in this that induced anxiolysis and hypnosis.

To guarantee the masking to the viewer, which was the treating anesthesiologist, a nurse was trained in the adjustment of the infusion balloon. Ten minutes before concluding the procedure and by request of the anesthesiologist, the nurse proceeded to locate balloon in such a way that the infusion could not be seen by the anesthesiologist, then opened the envelope and adjusted the infusion according to the randomization (U) o (T). The evaluation of the cough, its intensity and the Ramsay were under the care of the anesthesiologist, who was unaware of the awakening infusion.

Allocation:

Two were allocated for the use: Concentration of remifentanil of 2 - 3 ng/ml (group U) and concentration of remifentanil of 3 - 4 ng/ml (group T).

Recruitment:

A patient was recruited between the period of January 2011 and July 2012.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

110

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Valle del Cauca
      • Santiago de Cali, Valle del Cauca, Colombia, 288 00
        • Instituto Para Niños Ciegos y Sordos del Valle del Cauca

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • All patients aged 18-70 years
  • Risk Scale American Society of Anaesthesiologists physical status classification (ASA) I and II
  • Undergoing elective ear surgery

Exclusion Criteria:

  • Patients who are contraindicated remifentanil
  • Patients undergoing emergency surgery
  • Pulmonary Pathology (ASTHMA - COPD)
  • Index of body mass greater than 35
  • Background of respiratory failure three weeks prior to the procedure
  • Smokers

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Extubation U
Remifentanil concentration between 2 - 3 ng/ml.

Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:

  • 20 years old - 6.0 mcg/Kg/h
  • 30 years old - 5.7 mcg/Kg/h
  • 40 years old - 5.3 mcg/kg/h
  • 50 years old - 5.0 mcg/kg/h
  • 60 years old - 4.6 mcg/kg/h
  • 70 years old - 4.3 mcg/kg/h
  • 80 years old - 4.0 mcg kg/h.
Andere namen:
  • Ultiva
Experimenteel: Extubation T
Remifentanil concentration between 3 - 4 ng/ml

Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:

The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.

The remifentanil dose was adjusted according to the randomization:

  • 20 years old - 9.0 mcg/Kg/h
  • 30 years old - 8.5 mcg/Kg/h
  • 40 years old - 8.0 mcg/kg/h
  • 50 years old - 7.5 mcg/kg/h
  • 60 years old - 7.0 mcg/kg/h
  • 70 years old - 6.5 mcg/kg/h
  • 80 years old - 6.0 mcg kg/h.
Andere namen:
  • Ultiva

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cough
Tijdsspanne: It is evaluated by the scale of cough over a two hour period after surgery: is assessed at 5 minutes turned off the halogenated inhalation anesthetics, thereafter every minute until the patient responds to verbal stimulus and can be extubated

Number of episodes and duration of cough that occur when the patient responds to verbal stimulus and extubated.

Cough Scale

  • Grade 0 = No cough
  • Grade 1 = Mild (only episode of cough)
  • Grade 2 = Moderate (more than 1episode of cough during less than 5 seconds)
  • Grade 3 = Severe (More than one episode of cough that lasted more than 5 seconds or purposeless movements of the extremities).
It is evaluated by the scale of cough over a two hour period after surgery: is assessed at 5 minutes turned off the halogenated inhalation anesthetics, thereafter every minute until the patient responds to verbal stimulus and can be extubated

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Wake time.
Tijdsspanne: During two hours after surgery, five minutes after turning off halogenated inhaled anesthetics, then every minute until the patient opens his eyes and is extubated.

When vaporizer where closed until the patient responds to the verbal stimulus and is extubated.

Defined as the time taken to open eyes after having turned off the halogenated inhalation anesthetics.

During two hours after surgery, five minutes after turning off halogenated inhaled anesthetics, then every minute until the patient opens his eyes and is extubated.
Ramsay scale at the time of extubation
Tijdsspanne: During two hours after surgery, the estimated time period during which the event was assessed five (5) minutes after every minute, until answered

Ramsay scale: score objective system for measuring drug-induced sedation

  • Score 1: Anxious or restless or both
  • Score 2: Cooperative, orientated and tranquil
  • Score 3: Responding to commands
  • Score 4: Brisk response to stimulus
  • Score 5: Sluggish response to stimulus
  • Score 6: No response to stimulus
During two hours after surgery, the estimated time period during which the event was assessed five (5) minutes after every minute, until answered

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: LUIS A TAFUR, MD, Seganest
  • Studie directeur: Eduardo Lema, MD, Seganest

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 januari 2011

Primaire voltooiing (Werkelijk)

1 januari 2011

Studie voltooiing (Werkelijk)

1 juli 2012

Studieregistratiedata

Eerst ingediend

27 augustus 2013

Eerst ingediend dat voldeed aan de QC-criteria

16 maart 2016

Eerst geplaatst (Schatting)

17 maart 2016

Updates van studierecords

Laatste update geplaatst (Schatting)

17 maart 2016

Laatste update ingediend die voldeed aan QC-criteria

16 maart 2016

Laatst geverifieerd

1 maart 2016

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Nee

Beschrijving IPD-plan

The individual data of the participants (IPD) were only available to the ethics committee of the institution.

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

3
Abonneren